Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Feb 28, 2025

COVID-19 Vaccine Tickers $NVAX, $MRK, $PFE, $JNJ, $INO, and $MRNA Surge +7.7% in Weekly Performance

Robots for this industry :
Choppy Market Trader for Beginners: Medical Stocks (TA&FA)
Swing Trader for Beginners: Trading in Markets Trending Down (TA&FA)

In a remarkable turn of events, Covid-19 vaccine companies have shown a robust performance, boasting a significant increase of 7.7% in the past week. This surge is driven by a selection of key players in the field, including NVAX, MRK, PFE, JNJ, INO, and MRNA. These stocks are currently exhibiting a positive outlook, supported by a comprehensive analysis of 15 indicators, with the Tickeron Fear & Greed Index reflecting an optimistic sentiment. Furthermore, Tickeron's predictive analytics suggest a potential increase of more than 4.00% within the next month, with a likelihood of 63%. Over the past month, the daily ratio of advancing to declining volumes stood at 1 to 1.59, indicating a balanced and stable market.

Market Cap Overview

The Covid-19 vaccine theme is associated with an average market capitalization of approximately $145.4 billion. This reflects the diverse range of market caps within this theme, with values spanning from $135.7 million to $376.1 billion. Johnson & Johnson (JNJ) leads the pack in terms of valuation, with a substantial market cap of $376.1 billion, while Inovio Pharmaceuticals (INO) is the lowest valued company in this group, with a market cap of $135.7 million. However, it's worth noting that the market cap of JNJ experienced significant fluctuations recently, dropping by $25.6 billion on August 26, 2023, and suffering a staggering $85.2 billion decrease just a few months prior.

Price Movements and Notable News

When considering the price movements across all stocks within the Covid-19 vaccine theme, there's a notable weekly price growth of 7.7%. However, the monthly average price growth stands at -0.01%, and the quarterly average is -20.08%. INO stands out as the top gainer, experiencing a remarkable price growth of 42.43%. On the flip side, MRNA encountered a substantial decline, with a -1.44% decrease.

Recent highlights include Inovio Pharmaceuticals (INO) as a top weekly gainer for penny stocks, achieving an impressive 33.49% rise. Meanwhile, Moderna (MRNA) demonstrated strength by gaining 5.23%, and Pfizer (PFE) faced headwinds, declining by 5.14%.

Volume Growth Insights

In terms of volume growth, the average weekly increase across all stocks in the Covid-19 vaccine theme is a substantial 25.99%. When looking at monthly trends, the average growth surges to 92.96%, and the quarterly growth is still notable at 57.23%. There are instances, such as those on 7/6/23 and 6/24/23, where the volume for Inovio Pharmaceuticals surged, achieving record-breaking daily growth of 256% and 278%, respectively, of the 65-Day Volume Moving Average.

Technical Analysis on Key Stocks

  1. MRK - Stochastic Oscillator Ascends Out of Oversold Territory On October 6, 2023, the Stochastic Indicator for MRK moved out of oversold territory, signaling a potential bullish trend. Historical data analyzed by Tickeron's A.I.dvisor reveals that in 76% of similar instances, the stock moved higher in the following days. The current price of $103.45 is within the range of $101.93 support and $115.46 resistance, showing a positive uptrend during the week of 10/03/23 - 10/10/23.

  2. PFE - RSI Indicator Indicates an Uptrend The RSI Indicator for PFE emerged from oversold territory on September 29, 2023, hinting at a potential shift from a downward trend to an upward one. In 71% of comparable cases, stocks moved higher after such an occurrence. The current price of $33.10 is within the range of $30.56 support and $40.90 resistance, although it faced a slight decline during the week of 10/03/23 - 10/10/23.

  3. JNJ - RSI Oscillator Shows Signs of Uptrend On October 5, 2023, the RSI Indicator for JNJ left oversold territory, suggesting a possible transition from a downward trend to an upward one. Historical data indicates that in 56% of similar cases, the stock moved higher. The current price of $156.18 is trading between $150.88 support and $160.27 resistance, showcasing a recent uptrend during the week of 10/03/23 - 10/10/23.

In summary, the Covid-19 vaccine companies are experiencing a positive upswing in the market, with stocks in this theme demonstrating notable performance, bolstered by a series of key technical indicators. Investors should remain vigilant and consider these analyses while making informed decisions in this dynamic market environment.


Contributor

Dem Sem's AvatarDem Sem|Expert

Interact to see
Advertisement
C3.ai (AI) dropped more than 18% today after delivering a deeply disappointing quarterly report, slashing its revenue outlook, and announcing mass layoffs, which together reinforced doubts about its growth story in an increasingly competitive AI software market.
On the surface, PRCT’s top line still grew: Q4 2025 revenue reached about 76.4 million dollars, up roughly 11.9–12% from the prior year. However, analysts had expected something closer to 94–96 million dollars, so the shortfall of nearly 20% was significant for a high‑growth med‑tech name.
Payoneer Global (PAYO) fell more than 18% today after it missed Wall Street expectations on both Q4 2025 revenue and earnings, and issued softer‑than‑hoped guidance that reinforced concerns about slowing growth and competitive pressure in cross‑border fintech.
Gold, uranium, and rare earth stocks are moving fast in 2026 — and this 15-minute AI Trading Agent is built to move faster. Designed for high-beta Mining & Metals leaders like NEM, LEU, MP, and KGC, it transforms commodity volatility into structured, data-driven opportunity with institutional-grade risk control.
In a market where milliseconds matter and emotional decisions cost fortunes, a new class of AI-driven trading tools is rewriting the rulebook. Meet the HUBB, AVGO, ITA, QQQ – Trading Results AI Trading Agent (4 Tickers, 5min) — a precision-engineered robot that monitors four strategically selected tickers across semiconductors, industrial power infrastructure, aerospace & defense, and broad tech growth.
Q4 2025 gross profit grew about 24% year over year to roughly 2.87 billion dollars, with Cash App gross profit up about 33% and Square gross profit up around 7%. Adjusted operating income jumped to about 588 million dollars in Q4 (around a 20% margin), up strongly from the prior year. For the full year, gross profit was roughly 10.36 billion dollars, up about 17% year over year, showing broad‑based growth across the business.
NVDA shares declined 5.47% on Thursday, February 26, 2026, closing at $184.87, down from the prior session close of approximately $195.56. The primary catalyst was a "sell the news" reaction to Q4 fiscal 2026 earnings that beat estimates on every headline metric but failed to ignite meaningful buying interest.
Shares of UHS fell approximately 9.15% on February 26, 2026, closing near $209.62, down from a prior close of $230.73. The primary catalyst was a mixed Q4 2025 earnings report: adjusted EPS of $5.88 missed the consensus estimate of $5.92, and revenue of $4.49 billion fell short of the $4.50–$4.51 billion analyst forecast.
HEI shares fell approximately 9.21% on February 26, 2026, closing at $312.98 versus a prior close near $344.72. The primary catalyst was HEICO's Q1 fiscal 2026 earnings report, which delivered headline beats on EPS and revenue but disappointed investors on margin quality, Adjusted EBITDA, and cash flow generation.
IONQ surged +21.70% on February 26, 2026, closing at $40.88 versus the prior session's close of $33.59. The primary catalyst was a powerful Q4 and full-year 2025 earnings beat, with annual revenue of $130 million coming in 20% above guidance and representing 202% year-over-year growth.
Shares of CRWV declined approximately 11.38% in Friday's session, falling from a prior close of $97.63 to around $86.52, after the company reported Q4 2025 earnings after the bell on Thursday, February 26. The primary catalyst was a wider-than-expected net loss of $0.56 per share on EPS expectations of −$0.49, alongside a massive capex plan calling for $30–$35 billion in infrastructure spending in 2026, more than doubling the prior year.
DELL shares surged 16.64% during Friday's session, last trading around $141.65, up from the prior close of $121.45. The primary catalyst was a blowout Q4 fiscal year 2026 earnings report, with revenue of $33.4 billion — up 39% year-over-year — beating consensus estimates by roughly $2 billion.
Stifel Financial (SF) appears to be down over 30% on your screen today primarily because its shares began trading split‑adjusted following a three‑for‑two stock split (a 50% stock dividend), not because of a sudden collapse in the company’s fundamentals. After the split, the per‑share price is mechanically lower, even though the underlying value of the business has not changed.
Sunrun (RUN) sank more than 35–37% today even after posting a massive Q4 beat because its outlook and strategic commentary signaled slower volume growth, tighter financing conditions, and a more defensive stance on 2026, which together triggered a sharp reset in already‑volatile solar sentiment.
PAR Technology Corp. (PAR) dropped more than 28% today after its latest earnings report, even though it beat on revenue and EPS, because investors focused on weak profitability, continued operating losses, and a wave of sharply lower analyst price targets that signaled reduced confidence in the stock’s near‑term upside.
Carter’s (CRI) dropped more than 21% today because, even though it beat Q4 expectations on both sales and earnings, management issued a much weaker 2026 earnings outlook, highlighted ongoing margin pressure from tariffs and product costs, and guided to a sharp near‑term EPS drop that jarred investors.
WES is an oil & gas midstream partnership (NYSE: WES) with largely fee‑based, long‑term volume contracts in key basins such as the Delaware and DJ, which insulate cash flows from direct oil price swings but still tie them to producer activity and throughput. Current positioning: The units trade around 41–42 dollars with a high cash yield (roughly 9% dividend), solid profitability (P/E about 14), and strong returns on equity above 40%, signaling a mature, cash‑generative infrastructure asset.
SD is a pure‑play upstream energy company with operations concentrated in U.S. onshore oil and gas, so its revenues are directly influenced by global oil and gas price movements.
TTI is an oilfield services and specialty chemicals company, not a direct oil producer, so it tends to benefit when higher oil prices lead to sustained drilling and completion activity rather than from price moves alone. The Iran war raises the odds of major supply disruptions, and several commentators see a path to Brent near 100 dollars per barrel if the Strait of Hormuz is impaired, which would support energy capex and, by extension, demand for TTI’s services and fluids.
COP is a global upstream heavyweight, producing more than 2.3 million barrels of oil equivalent per day and generating over 60 billion dollars in annual revenue, with a strategy centered on disciplined capex and robust cash returns to shareholders. The Iran war introduces a structural risk premium into oil markets; if supply from the region or traffic through Hormuz is disrupted, analysts see Brent potentially trading nearer 90–100 dollars per barrel or higher, which is supportive for ConocoPhillips’ cash flows and valuation.